# A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors

> **NCT02650713** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 228 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** RO6958688

## Key facts

- **NCT ID:** NCT02650713
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-07
- **Primary completion:** 2020-01-13
- **Final completion:** 2020-01-13
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2020-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02650713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02650713, "A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02650713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*